Noteworthy, systemic anti-inflammatory effects of anti-diabetic medication are increasingly considered [25], such as metformin [26, 27], glucagon-like peptide-1 analogs [28], sulfonylureas [29], thiazolidinedione, DPP-4 inhibitors [30] and insulin [31]; all of them are inhibitors of NF-κB which plays a central role in COPD-associated inflammation [32]. This evidence concerns the gene GCG and chronic obstructive pulmonary disease.